Close Menu

NEW YORK – Myriad Genetics is hoping new data and the recent inclusion in society guidelines will drive adoption and payor coverage of its Vectra proteomic test for rheumatoid arthritis.

The company's Myriad Autoimmune business unit presented a pair of studies at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting last month that demonstrated the ability of the test to predict a patient's risk of radiographic progression and risk of suffering a major cardiovascular event.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.